efalizumab


Also found in: Wikipedia.

efalizumab

a rarely used immunosuppressant.
indications This drug is used in adults 18 years of age and older to treat moderate to severe plaque psoriasis.

efalizumab

A recombinant, humanized monoclonal antibody to CD11 a used to treat moderate to severe PSORIASIS.
Mentioned in ?
References in periodicals archive ?
6,10) More recently, biologic agents have been implicated in SSLR, including rituximab, efalizumab, and infliximab.
Serum sickness
001) Dermatology revealed study which studied efficacy of efalizumab in patients with moderate-to-severe psoriasis after 16 weeks of treatment patients with PASI 75 were 71% compared to PGA 0, 1 showing 62% showing that PASI show better improvement than PGA.
Evaluation of efficacy of indices in psoriasis in relation to severity and improvement in therapy
Favourable responses to photochemotheray with or without acitretin, etretinate, photodynamic therapy and efalizumab have been reported but further studies are called for regarding these therapies.
Keratosis lichenoides chronica: case report
Ng noted that a trial of efalizumab (Raptiva) had terminated because of an increased risk for progressive multifocal leukoencephalopathy.
TRACTISS ends rituximab hopes for Sjogren's syndrome
Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
Late onset pityriasis rubra pilaris type IV treated with low-dose acitretin
Refractory Subacute Cutaneous Lupus Erythematosus With a Response to Efalizumab.
Lupus eritematoso cutaneo: analisis clinicos y de laboratorio
More recently, PML has been reported in patients being treated with immunosuppressive drugs, including efalizumab (withdrawn from the market), infliximab, mycophenolate mofetil, rituximab, and most notably, natalizumab.
A 31-year-old man who presents with speech abnormalities
Efalizumab for severe atopic dermatitis: a pilot study in adults.
Allergen immunotherapy, when and why?/Inmunoterapia con alergenos, ?cuando y por que?/Imunoterapia com alergenos, quando e por que?
Infliximab, efalizumab, tocilizumab and rituximab have been studied in this regard, but no firm recommendations can be provided at this stage.
Topical and systemic pharmacological treatment of atopic dermatitis
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Lymphocyte adhesion and autoimmunity
Efalizumab is a recombinant humanised monoclonal IgG1 antibody that binds to CD11a, a subunit of leukocyte function-associated antigen 1 (LFA-1) (24).
Biologies in dermatology: a brief review
Efalizumab (Raptiva), injected by patients once a week
Learn the connection between psoriasis and heart disease: research shows that this common skin condition can increase your risk of cardiovascular problems

Medical browser ?
Full browser ?